Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction

American Journal of Therapeutics
Norman C WangEVEREST Investigators

Abstract

The aim of this study was to investigate the association between implantable cardioverter-defibrillator (ICD) status at the time of hospitalization for worsening heart failure (HF) with postdischarge events in patients with reduced left ventricular ejection fraction. We conducted an analysis of 4133 patients hospitalized for HF with left ventricular ejection fraction 40% or less in EVEREST. The final analysis included patients without an electrophysiological device (n = 3102) and those with an ICD (n = 600) at the time of enrollment. During a median follow-up of 300 days, all-cause mortality was 22.9% in the no device group and 35.2% in the ICD group (hazard ratio [HR], 1.62; 95% confidence interval [CI], 1.39-1.89). Rehospitalization for HF was 27.0% in the no device group and 46.8% in the ICD group (HR, 2.20; 95% CI, 1.92-2.52). After adjustment for multiple variables, the rates for all-cause mortality were similar (HR, 1.01; 95% CI, 0.83-1.22), but the ICD group had elevated rates of HF hospitalizations compared with the no device group (HR, 1.35; 95% CI, 1.14-1.60). In patients with reduced left ventricular ejection fraction, an ICD at presentation for hospitalization for worsening HF was associated with similar rates of de...Continue Reading

References

Feb 19, 1999·Lancet
Mar 22, 2002·The New England Journal of Medicine·Arthur J MossUNKNOWN Multicenter Automatic Defibrillator Implantation Trial II Investigators
Jan 3, 2003·JAMA : the Journal of the American Medical Association·Bruce L WilkoffUNKNOWN Dual Chamber and VVI Implantable Defibrillator Trial Investigators
Jan 22, 2005·The New England Journal of Medicine·Gust H BardyUNKNOWN Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators
Dec 21, 2005·Circulation·Mihai GheorghiadeUNKNOWN International Working Group on Acute Heart Failure Syndromes
Aug 17, 2006·Journal of Cardiac Failure·Lynne Warner Stevenson, Akshay S Desai
Dec 30, 2006·Circulation·Wayne RosamondUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Mar 27, 2007·JAMA : the Journal of the American Medical Association·Marvin A KonstamUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
Mar 27, 2007·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
Dec 18, 2007·American Heart Journal·Gad CotterChristopher M O'Connor
Jun 12, 2008·JAMA : the Journal of the American Medical Association·Norman C WangUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
Jul 16, 2008·Archives of Internal Medicine·Joseph S RossHarlan M Krumholz
Sep 5, 2008·The New England Journal of Medicine·Jeanne E PooleGust H Bardy
Feb 14, 2009·Journal of the American College of Cardiology·Mihai Gheorghiade, Peter S Pang
Apr 3, 2009·The New England Journal of Medicine·Stephen F JencksEric A Coleman
May 4, 2010·American Heart Journal·Christopher M O'ConnorUNKNOWN Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) investigators

❮ Previous
Next ❯

Citations

Mar 25, 2011·Heart Failure Reviews·Norman C WangMihai Gheorghiade
Aug 2, 2011·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Larisa G TereshchenkoCharles D Swerdlow
Oct 11, 2014·Journal of the American College of Cardiology·Stephen J Greene, Mihai Gheorghiade
Nov 23, 2010·Journal of Cardiovascular Electrophysiology·Peter StempniewiczLarisa G Tereshchenko
Dec 12, 2012·Journal of the American College of Cardiology·Mihai GheorghiadeRobert O Bonow
Apr 2, 2013·Journal of the American College of Cardiology·Chih-Ying ChenSoko Setoguchi
May 13, 2017·Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·Norman C WangSamir Saba
Oct 31, 2017·European Journal of Heart Failure·Baljash CheemaMihai Gheorghiade
Jul 10, 2018·American Journal of Therapeutics·Ovidiu ChioncelAlexandre Mebazaa
May 8, 2018·The American Journal of Cardiology·Muthiah VaduganathanFaiez Zannad

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.